FI3123381T3 - Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä - Google Patents

Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä Download PDF

Info

Publication number
FI3123381T3
FI3123381T3 FIEP15768735.1T FI15768735T FI3123381T3 FI 3123381 T3 FI3123381 T3 FI 3123381T3 FI 15768735 T FI15768735 T FI 15768735T FI 3123381 T3 FI3123381 T3 FI 3123381T3
Authority
FI
Finland
Prior art keywords
capture antibody
var
tpsa
prostate
biopsy
Prior art date
Application number
FIEP15768735.1T
Other languages
English (en)
Finnish (fi)
Inventor
David Steinmiller
Vincent Linder
Kim Pettersson
Timo Lovgren
Hans Lilja
Peter Scardino
Andrew Vickers
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Application granted granted Critical
Publication of FI3123381T3 publication Critical patent/FI3123381T3/fi

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Primary Health Care (AREA)
  • Genetics & Genomics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Bioethics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FIEP15768735.1T 2014-03-28 2015-03-27 Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä FI3123381T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28
PCT/US2015/023096 WO2015148979A1 (en) 2014-03-28 2015-03-27 Compositons and methods related to diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
FI3123381T3 true FI3123381T3 (fi) 2023-11-27

Family

ID=54196462

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15768735.1T FI3123381T3 (fi) 2014-03-28 2015-03-27 Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä

Country Status (24)

Country Link
US (2) US11761962B2 (https=)
EP (2) EP3123381B1 (https=)
JP (3) JP6775488B2 (https=)
KR (1) KR102505543B1 (https=)
CN (2) CN114740202A (https=)
AR (1) AR099883A1 (https=)
AU (1) AU2015237270B2 (https=)
CA (1) CA2944001C (https=)
CL (1) CL2016002419A1 (https=)
DE (1) DE202015009668U1 (https=)
DK (1) DK3123381T3 (https=)
EA (1) EA201691952A1 (https=)
ES (1) ES2964706T3 (https=)
FI (1) FI3123381T3 (https=)
HU (1) HUE065029T2 (https=)
IL (2) IL247981B (https=)
MX (2) MX392384B (https=)
MY (1) MY192513A (https=)
PE (1) PE20170298A1 (https=)
PL (1) PL3123381T3 (https=)
PT (1) PT3123381T (https=)
SG (2) SG10201808585TA (https=)
TW (1) TWI687688B (https=)
WO (1) WO2015148979A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152417B1 (en) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Device and method for analyses in microfluidic systems
ES2695039T3 (es) 2009-02-02 2018-12-28 Opko Diagnostics, Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
TWI596494B (zh) 2012-03-05 2017-08-21 Ｏｐｋｏ診斷法有限責任公司 預測前列腺癌風險及前列腺腺體體積之方法及裝置
US12326453B2 (en) * 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
PT3253800T (pt) * 2015-03-27 2021-04-28 Opko Diagnostics Llc Padrões de antigénio da próstata e suas utilizações
LT3359189T (lt) * 2015-10-05 2021-07-26 Fredax Ab Humanizuoti anti-psa (5a10) antikūnai
CA3005084A1 (en) 2015-12-11 2017-06-15 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
JP6956719B2 (ja) 2015-12-29 2021-11-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 流体の収集のための物品
WO2018129414A1 (en) * 2017-01-08 2018-07-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Systems and methods for using supervised learning to predict subject-specific pneumonia outcomes
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
ES3040560T3 (en) * 2019-10-11 2025-11-03 C The Signs Ltd Diagnostic tool
KR102730255B1 (ko) * 2022-08-12 2024-11-15 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도
CN118629514B (zh) * 2024-08-08 2024-10-29 上海橙帆医药有限公司 序列免疫原性预测方法、装置、电子设备及存储介质

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
DE69433688T2 (de) 1993-10-28 2005-04-28 I-Stat Corp. Vorrichtung zur abnahme und einleitung von flüssigkeitsproben
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
JPH11510601A (ja) 1995-08-03 1999-09-14 アクゾ・ノベル・エヌ・ベー 診断装置
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
CA2360073C (en) 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
EP1328342A4 (en) 2000-10-10 2006-03-15 Aviva Biosciences Corp INTEGRATED BIOCHIP SYSTEM FOR SAMPLE PREPARATION AND ANALYSIS
JP2004536278A (ja) 2000-11-20 2004-12-02 イースタン・ヴァージニア・メディカル・スクール 前立腺特異的膜抗原、その他の前立腺マーカーの定量的検出方法及び装置
WO2003029427A2 (en) 2001-10-03 2003-04-10 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
US7258837B2 (en) 2001-12-05 2007-08-21 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
AU2003242389A1 (en) 2002-05-28 2003-12-12 Jokoh Co., Ltd Immunological chromatograph method test slip reading/quantitative determination device
NZ562192A (en) 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
AU2004209578A1 (en) * 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
US20050118061A1 (en) 2003-11-28 2005-06-02 Sysmex Corporation Analyzer, assay cartridge and analyzing method
WO2005056186A1 (en) 2003-12-10 2005-06-23 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A modular biochip assembly
US7736890B2 (en) 2003-12-31 2010-06-15 President And Fellows Of Harvard College Assay device and method
JP4698613B2 (ja) 2004-01-26 2011-06-08 プレジデント アンド フェロウズ オブ ハーバード カレッジ 流体送達のシステムおよび方法
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
CA2564208A1 (en) 2004-05-11 2005-11-24 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
MX2007001357A (es) 2004-08-02 2009-08-07 Childrens Medical Center Biomarcadores de plaquetas para cancer.
WO2006034032A2 (en) 2004-09-17 2006-03-30 The Johns Hopkins University Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122312A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Methods of testing using a microfluidic cassette
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
CN101454331A (zh) 2006-03-24 2009-06-10 菲诺梅诺米发现公司 有效用于诊断前列腺癌的生物标记，及其方法
JP2009540852A (ja) 2006-07-03 2009-11-26 エグゾニ・テラピューティック・ソシエテ・アノニム 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
CN101588815B (zh) 2006-12-22 2013-10-23 法蒂亚公司 新前列腺激肽释放酶过敏原
EP2152417B1 (en) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Device and method for analyses in microfluidic systems
AU2008251877A1 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
CN101861522B (zh) 2007-10-22 2014-05-14 圣文森特医院悉尼有限公司 预后方法
US20090226912A1 (en) 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
KR20110086074A (ko) 2008-10-20 2011-07-27 리포사이언스, 인크. 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2010080115A2 (en) 2008-12-18 2010-07-15 Claros Diagnostics, Inc. Improved reagent storage in microfluidic systems and related articles and methods
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
ES2695039T3 (es) 2009-02-02 2018-12-28 Opko Diagnostics, Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
US20120122243A1 (en) * 2009-06-04 2012-05-17 Charite Universitatsmedizin Berlin Means and method and means for diagnosing prostate carcinomas
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
BR112012026366B1 (pt) 2010-04-16 2020-05-05 Opko Diagnostics, Llc analisador de amostras microfluídicas e método para analisar uma amostra microfluídica
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
US20140227720A1 (en) 2011-06-09 2014-08-14 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
JP6072686B2 (ja) 2011-07-21 2017-02-01 和光純薬工業株式会社 血漿中アミノ酸分析用標準液
KR102362358B1 (ko) 2011-10-28 2022-02-15 프레닥스 에이비 치료제 및 이의 용도
WO2013106778A2 (en) 2012-01-13 2013-07-18 Iris International, Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
TWI596494B (zh) 2012-03-05 2017-08-21 Ｏｐｋｏ診斷法有限責任公司 預測前列腺癌風險及前列腺腺體體積之方法及裝置
EP2850432A2 (en) 2012-05-16 2015-03-25 Phadia AB Method for indicating the presence or non-presence of prostate cancer
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US10431326B2 (en) 2012-11-20 2019-10-01 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
EP2922970B1 (en) 2012-11-20 2018-08-08 Phadia AB Prognostic method for individuals with prostate cancer
HUE043875T2 (hu) 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest
FI3117216T3 (fi) 2014-03-11 2023-04-27 Phadia Ab Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
US10217619B2 (en) 2015-03-12 2019-02-26 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed intact protein analytes
PT3253800T (pt) 2015-03-27 2021-04-28 Opko Diagnostics Llc Padrões de antigénio da próstata e suas utilizações
KR102527446B1 (ko) 2015-04-29 2023-05-02 옵코 다이어그노스틱스, 엘엘씨 전립선암의 적극적 감시를 위한 조성물 및 방법
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
EP3794354A4 (en) 2018-05-16 2022-01-12 Opko Diagnostics, LLC METHODS OF DETECTING PROSTATE CANCER ASSOCIATED WITH NEGATIVE RESULTS

Also Published As

Publication number Publication date
JP7506131B2 (ja) 2024-06-25
AR099883A1 (es) 2016-08-24
CN114740202A (zh) 2022-07-12
AU2015237270B2 (en) 2021-09-09
JP2017515127A (ja) 2017-06-08
JP7256781B2 (ja) 2023-04-12
DK3123381T3 (da) 2023-11-27
MX392384B (es) 2025-03-24
MY192513A (en) 2022-08-24
KR102505543B1 (ko) 2023-03-02
CA2944001A1 (en) 2015-10-01
EP3123381A1 (en) 2017-02-01
WO2015148979A8 (en) 2016-01-07
CN106663149A (zh) 2017-05-10
AU2015237270A1 (en) 2016-10-20
EA201691952A1 (ru) 2017-05-31
EP3123381B1 (en) 2023-10-11
MX2016012667A (es) 2017-01-09
SG11201608035UA (en) 2016-10-28
US20160025732A1 (en) 2016-01-28
CL2016002419A1 (es) 2017-03-31
PL3123381T3 (pl) 2024-02-26
IL247981B (en) 2021-02-28
US20230393137A1 (en) 2023-12-07
MX2022002365A (es) 2022-04-06
EP3123381A4 (en) 2018-02-21
ES2964706T3 (es) 2024-04-09
HUE065029T2 (hu) 2024-04-28
EP3299977A1 (en) 2018-03-28
DE202015009668U1 (de) 2019-01-21
BR112016022407A2 (pt) 2017-12-12
WO2015148979A1 (en) 2015-10-01
IL280039A (en) 2021-03-01
JP2021009157A (ja) 2021-01-28
PE20170298A1 (es) 2017-04-18
JP6775488B2 (ja) 2020-10-28
US11761962B2 (en) 2023-09-19
TWI687688B (zh) 2020-03-11
PT3123381T (pt) 2023-12-22
IL280039B (en) 2021-12-01
CA2944001C (en) 2023-08-15
IL247981A0 (en) 2016-11-30
TW201621320A (zh) 2016-06-16
SG10201808585TA (en) 2018-11-29
KR20170008729A (ko) 2017-01-24
JP2023017841A (ja) 2023-02-07

Similar Documents

Publication Publication Date Title
FI3123381T3 (fi) Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä
Kaido et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma
Uzozie et al. Targeted proteomics for multiplexed verification of markers of colorectal tumorigenesis
Wang et al. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation
Woo et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas
Angeletti et al. Diagnostic and prognostic role of procalcitonin (PCT) and MR‐pro‐Adrenomedullin (MR‐pro ADM) in bacterial infections
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
Nel et al. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma
Kayser et al. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas
WO2017139587A3 (en) Anti-dengue virus ns1 protein monoclonal antibodies
HRP20191690T1 (hr) Molekule anti-gcc antitijela i njihova uporaba u ispitivanju osjetljivosti na gcc-ciljanu terapiju
NZ602056A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Zhang et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis
Honing et al. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy
He et al. Detection of circulating tumour cells with the CellSearch system in patients with advanced-stage head and neck cancer: preliminary results
Suzuki et al. Intratumoral FOXP3+ VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
Bunatova et al. Plasma TIMP1 level is a prognostic factor in patients with liver metastases
EP1778880A4 (en) METHOD AND REAGENT FOR DIAGNOSIS OF HANTAVIRUS INFECTIONS
EP3159695A3 (en) Methods for diagnosing pancreatic cancer
Fehm et al. Detection of disseminated tumor cells in patients with gynecological cancers
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
Liu et al. A novel prognostic score, based on preoperative nutritional status, predicts outcomes of patients after curative resection for gastric cancer
Tang et al. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma
Hida et al. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis